SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Sharon Bio Medicine rallies on receiving EIR from USFDA for Taloja plant

21 Sep 2016 Evaluate

Sharon Bio-Medicine is currently trading at Rs. 12.19, up by 2.03 points or 19.98% from its previous closing of Rs. 10.16 on the BSE.

The scrip opened at Rs. 11.70 and has touched a high and low of Rs. 12.19 and Rs. 11.69 respectively. So far 2311369 shares were traded on the counter.

The BSE group 'B' stock of face value Rs. 2 has touched a 52 week high of Rs. 32.55 on 16-Dec-2015 and a 52 week low of Rs. 8.25 on 16-Sep-2016.

Last one week high and low of the scrip stood at Rs. 12.19 and Rs. 8.25 respectively. The current market cap of the company is Rs. 144.98 crore.

The promoters holding in the company stood at 52.26%, while Institutions and Non-Institutions held 5.03% and 42.71% respectively.

Sharon Bio Medicine has received the Establishment Inspection Report (EIR) from United States Food and Drug Administration (USFDA) conducted during period ranging from June 29, 2015 to July 7, 2015 at Active Pharmaceutical Ingredient (API) plant located at L-6, MIDC, Taloja, Dist. Raigad, Maharshtra. The API Plant now is approved by USFDA. The payment for Generic Drug User Fee (GDUFA Fees) is pending and therefore supply to the United States of America cannot be done unless pending arrears are cleared.

Sharon Bio-Medicine is into manufacturing and supply of Active Pharmaceutical Ingredients (APIs).

Peers
Company Name CMP
Sun Pharma Inds. 1675.20
Dr. Reddys Lab 1235.40
Cipla 1238.30
Zydus Lifesciences 942.55
Lupin 2324.25
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×